DNA2.0, the leading bioengineering solutions provider, today introduced the Electra Vector System, a universal cloning system for simple, scarless cloning. The Electra system is completely free from licensing restrictions and provides researchers from a large variety of disciplines a much-needed advantage to current cloning methodology.
Systems that facilitate easy movement of DNA elements from one context to another allow many genetic constructs to be rapidly built and tested. DNA2.0 has developed a simple, PCR-free, one-tube universal cloning process that can be performed in a five-minute bench-top reaction with the fidelity of a restriction-based cloning system.
“For a cloning system to be truly universal, researchers should be able to easily utilize their constructs in multiple vector systems without licensing headaches. DNA2.0 developed the Electra Vector System because our customers deserve an efficient, rapid and reliable approach to cloning that is IP-Free,” said Jeremy Minshull, CEO and cofounder of DNA2.0. “Unlike alternative systems, with Electra there are no intellectual property entanglements, no unwanted mutations from polymerases and no sequence scars to affect expression and function.”
The Electra Vector System has 3 major components: pMOTHER vectors which contain the gene of interest, pDAUGHTER vectors (currently >100 vectors) for expression screening and the Electra Reagent Kit for one-step cloning. Electra DAUGHTER vectors are available for purchase independently from DNA2.0. Electra MOTHER vectors are available for individual purchase from the DNA2.0 catalog or by utilizing the DNA2.0 gene synthesis service.
The Electra system takes advantage of the type IIS restriction enzyme SapI developed by New England Biolabs. The key properties of SapI include a sufficiently rare 7bp non-palindromic recognition sequence and a 3bp 5’overhang after digestion that can be designed for any sequence (e.g., the universal ATG start codon and a universal STOP codon). The Electra system can also be used to combine multiple sequence elements simultaneously, facilitating the easy construction of combinatorial libraries, either in a single tube, or in individually enumerated combinations. Any vector can be easily ‘Electrafied’, i.e., converted to function as an Electra DAUGHTER vector, and DNA2.0’s Ph.D.-level customer support scientists can assist customers in determining the best cloning strategy for their research.
About DNA2.0
DNA2.0 is the leading bioengineering solutions provider. Founded in 2003, DNA2.0 offers an integrated pipeline of solutions for the research community, including gene design, optimization, synthesis and cloning, as well as platforms for protein and strain engineering. It is the fastest provider of synthetic genes—based in the US with a global customer base encompassing academia, government and the pharmaceutical, chemical, agricultural and biotechnology industries. DNA2.0 is by far the most published synthetic gene vendor, providing expert support to and collaboration with scientists. DNA2.0 explores novel applications for synthetic genes and is exploiting the synergy between highly efficient gene design and synthesis processes and new protein optimization technologies. DNA2.0’s tools and solutions are fueling the transformation of biology from a discovery science to an engineering discipline. The company is privately held and is headquartered in Menlo Park, Calif. For more information, please visit http://www.DNA20.com.